Dr. Luchuan Chen 陈路川
Chief Physician
Department of Gastrointestinal Tumor Surgery, Fujian Cancer Hospital, Fuzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of gastrointestinal tumors, including gastric, colorectal, liver, pancreatic, renal, bladder, and bone/soft tissue cancers, using open and laparoscopic minimally invasive techniques.
Dr. Chen is Administrative Director of Ward 7, Department of Gastrointestinal Tumor Surgery at Fujian Cancer Hospital. Dr. Chen leads provincial research projects, participates in national multi-center clinical trials, and serves on editorial boards for several journals. Dr. Chen has published dozens of papers in SCI-indexed and key national journals.
Professional roles
- Vice Chair, Upper Gastrointestinal Surgery Committee, Chinese Medical Doctor Association
- Vice Chair, Gastric Cancer Professional Committee, Fujian Cancer Prevention and Treatment Alliance
- Vice Chair, Digestive Tract Tumor Professional Committee, Fujian Anti-Cancer Association
- Standing Committee Member, Neuroendocrine Tumor Branch, China International Exchange and Promotion Association for Medical and Healthcare
Name order: in Chinese the family name comes first (Chen Luchuan). Papers usually list the name as Luchuan Chen or Chen L.
Selected publications
28 papers on PubMed matched by name and affiliation; 14 as first or senior author since 2016. Most recent first- or senior-author papers:
- Sci Rep, 2025 (senior author): Modified RECIST submodels and ordinal regression model predict neoadjuvant chemoimmunotherapy response in locally advanced gastric cancer. PubMed 41057487
- Front Genet, 2022 (senior author): High Expression of FCRLB Predicts Poor Prognosis in Patients With Colorectal Cancer. PubMed 35783274
- Front Genet, 2022 (senior author): Corrigendum: Bioinformatics Analysis Reveals an Association Between Cancer Cell Stemness, Gene Mutations, and the Immune Microenvironment in Stomach Adenocarcinoma. PubMed 35237303
- Int J Clin Exp Pathol, 2021 (senior author): Erratum: MicroRNA-451a targets caveolin-1 in stomach cancer cells. PubMed 35027999
- BMC Surg, 2021 (senior author): Prognostic value of preoperative body mass index for diabetic patients with non-metastasis gastric cancer: a single center experience. PubMed 34372800
- Front Oncol, 2021 (senior author): A 13-Gene Metabolic Prognostic Signature Is Associated With Clinical and Immune Features in Stomach Adenocarcinoma. PubMed 34235071
- BMC Cancer, 2021 (senior author): Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer. PubMed 34126957
- World J Gastroenterol, 2021 (senior author): Survival-associated alternative splicing events interact with the immune microenvironment in stomach adenocarcinoma. PubMed 34135559
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion